Epstein v. Enzo Biochem, Inc.

CourtDistrict Court, E.D. New York
DecidedSeptember 29, 2023
Docket2:23-cv-04282
StatusUnknown

This text of Epstein v. Enzo Biochem, Inc. (Epstein v. Enzo Biochem, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Epstein v. Enzo Biochem, Inc., (E.D.N.Y. 2023).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK ------------------------------------------------------------------X In re ENZO BIOCHEM DATA SECURITY LITIGATION, MEMORANDUM AND OPINION CV 23-4282 (GRB) (AYS)

-----------------------------------------------------------------X ANNE Y. SHIELDS, United States Magistrate Judge: Before the Court are competing motions for the appointment of interim lead counsel in this consolidated consumer class action in which Plaintiffs allege, inter alia, violations of Section 349 of the New York General Business Law (“NYGBL”), as well claims for negligence, negligence per se, breach of contract, and unjust enrichment. The movants are as follows: (1) Plaintiffs Eliana Epstein, Tony Johnson, Nino Khakhiashvili, Marie Netrosio, Steven Griffin, Mark Guthart, and Jeffrey Abraham (collectively, the “Epstein Movants”); (2) Plaintiffs Paula Magnani, Izza Hafeez Shah, and Marjorie Weinman (collectively, the “Magnani Movants”); (3) Plaintiff Melanie Wohl (“Wohl”); (4) Plaintiff Margo Kupinska (“Kupinska”); and, (5) Plaintiffs Gita Garfinkel and Dorinda Bynum (collectively, the “Garfinkel Movants”). For the following reasons, the Magnani Movants’ motion for appointment of interim class counsel is granted and the motions by the Epstein Movants, Wohl, Kupinska, and the Garfinkel Movants for such appointment are denied. BACKGROUND Plaintiff Eliana Epstein (“Epstein”) commenced this consumer class action on June 9, 2023, asserting claims for negligence, negligence per se, breach of contract, unjust enrichment, and violation of Section 349 of the NYGBL by Defendants, Enzo Biochem, Inc., Enzo Clinical Labs, Inc., and Lab Corporation of America Holdings (collectively, “Defendants”). Epstein alleges that Defendants’ computer systems were inadequately protected, allowing for a cyberattack that resulted in a data breach of sensitive personal information in the possession of Defendants. (Epstein Compl. ¶ 1.) Since the filing of Epstein’s Complaint, eighteen more putative class actions have been

filed in this District, each alleging similar facts. All eighteen pending actions have been consolidated into the initial action commenced by Epstein, which has been designated the Lead Action. (Docket Entry (“DE”) [25].) Citation to the facts alleged herein will be to Epstein’s Complaint. Defendant Enzo Biochem, Inc. (“Enzo”) is a global molecular diagnostics company that integrates clinical laboratories, life sciences and intellectual property. (Compl. ¶ 24.) As part of their business, Enzo receives and maintains protected health information and other sensitive information of thousands of customers, assuring customers that they make every reasonable effort to protect the information collected. (Id. ¶¶ 4, 25, 27.) On April 6, 2023, Enzo identified a ransomware attack on its computer network. (Id. ¶

42.) According to the May 31, 2023 breach notice (the “Breach Notice”) Enzo distributed, an “investigation determined that an unauthorized party accessed files on [its] systems between April 4, 2023 and April 6, 2023.” (Id. and Ex. A, annexed thereto.) The information accessed by the cyberattack included customers’ names, Social Security numbers, dates of service, and clinical test information. (Breach Notice, Ex. A.) Enzo began notifying customers of the data breach on or about May 31, 2023. (Id. ¶ 44.) Epstein commenced the first filed action in this district on June 9, 2023. As stated above, eighteen more actions have been filed to date. The Epstein Movants’ motion for appointment as interim lead counsel was filed on June 15, 2023. (DE [7].) On July 10, 2023, Judge Brown consolidated all of the then-pending actions and designated the Epstein action as the Lead Action. (DE [25].) Judge Brown further directed that any additional motions for appointment of interim lead counsel be filed by July 10, 2023. (Id.) The remaining movants filed their motions that same day. (DE [27], [28], [29], [31].) Pursuant to Judge Brown’s Individual Rules, as non-

dispositive motions, the within motions for appointment of interim lead counsel are automatically referred to the undersigned for decision. The Court now turns to the merits of the motions. DISCUSSION I. Legal Standard Rule 23(g)(3) of the Federal Rules of Civil Procedure provides that the Court “may designate interim counsel to act on behalf of a putative class before determining whether to certify the action as a class action.” Fed. R. Civ. P. 23(g)(3). “The appointment of interim lead counsel, among other things, clarifies responsibility for the protection of the interests of the putative class during pre-certification motions, discovery, and settlement activity.” Pearlman v.

Cablevision Sys. Corp., No. 10-CV-4992, 2011 WL 477815, at *2 (E.D.N.Y. Feb. 1, 2011) (citing Manual For Complex Litigation (Fourth) § 21.11 (4th ed. 2004)). In selecting interim class counsel, courts look to the criteria set forth in Rule 23(g)(1)(A) to determine the adequacy of class counsel: (i) the work counsel has done in identifying or investigating potential claims in the action; (ii) counsel’s experience in handling class actions, other complex litigation, and the types of claims asserted in the action; (iii) counsel’s knowledge of the applicable law; and, (iv) the resources counsel will commit to representing the class. See In re HSBC Bank USA, N.A., Debit Card Overdraft Fee Litig., No. 12-cv-6224, 2013 WL 3816597, at *10 (E.D.N.Y. July 22, 2013). This determination is based on “an analysis of class counsel’s qualifications and experience in general (including in representing classes and in similar lawsuits)[,] as well as a fact-specific analysis of the conduct of counsel in the lawsuit in which a class is to be certified and the resources counsel will commit to representing the class.” Huer Huang v. Shanghai City Corp., 459 F. Supp. 3d 580, 596 (S.D.N.Y. 2020).

In addition to the four factors set forth in Rule 23(g)(1)(A), a court may also consider “any other matter pertinent to counsel’s ability to fairly and adequately represent the interests of the class.” Fed. R. Civ. P. 23(g)(1)(B). These include: “(1) the quality of the pleadings; (2) the vigorousness of the prosecution of the lawsuits; and (3) the capabilities of counsel, . . . as well as whether counsel are qualified and responsible, . . . [whether] they will fairly and adequately represent all of the parties on their side, and . . . [whether] their charges will be reasonable.” In re Bank of Am. Corp. Securities, Derivative and ERISA Litig., 258 F.R.D. 260, 272 (S.D.N.Y. 2009) (citation and internal quotation marks omitted) (alterations in original). Furthermore, courts may consider whether the proposed counsel is sufficiently diverse to reflect the composition of the class. See, e.g., In re J.P. Morgan Chase Cash Balance Litig., 242 F.R.D. 265,

277 (S.D.N.Y. 2007) (stating that “it is important to all concerned that there is evidence of diversity, in terms of race and gender, of any class counsel [the court] appoint[s]”); but see Martin v. Blessing, 571 U.S. 1040, 403 (2013) (stating that it “seems quite farfetched to argue that class counsel cannot fairly and adequately represent a class unless the race and gender of counsel mirror the demographics of the class”). Although diversity is not a factor that is outcome-determinative, “the intuition underlying the diversity criterion is soundly grounded in the Court’s obligation to select counsel who will best represent the interests of the class.” City of Providence v. AbbVie Inc., 20-cv-5538, 2020 WL 6049139, at *6-7 (S.D.N.Y. Oct. 13, 2020). II.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Winkal Holdings, LLC v. Jpmorgan Chase Bank, N.A.
134 S. Ct. 638 (Supreme Court, 2013)
In re J.P. Morgan Chase Cash Balance Litigation
242 F.R.D. 265 (S.D. New York, 2007)
Sklar v. Bank of America Corp.
258 F.R.D. 260 (S.D. New York, 2009)
Deangelis v. Corzine
286 F.R.D. 220 (S.D. New York, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
Epstein v. Enzo Biochem, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/epstein-v-enzo-biochem-inc-nyed-2023.